#USA #Karyopharm #XPOVIO #Newton #Selinexor

Karyopharm Therapeutics' Financial Report for Q2 2025

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has released its financial results for the second quarter ended June 30, 2025. The company, dedicated to pioneering cancer therapies, continues to establish its presence in the oncology market through innovative research and promising clinical trials.

Key Financial Highlights

During the second quarter of 2025, Karyopharm reported a total revenue of $37.9 million. This shows a decrease compared to $42.8 million in the same period last year. A significant contributor to the revenue was the net product revenue of $29.7 million generated from its flagship product, XPOVIO (selinexor), marking a 6% increase from $28.0 million in Q2 2024.

The company reaffirms its total revenue guidance for 2025, predicting an estimated $140 million to $155 million. It anticipates net product revenue from XPOVIO in the range of $110 million to $120 million for the full year. Karyopharm is actively exploring financing options and strategic alternatives to support its cash flow and enhance operational efficiency.

Clinical Developments

Karyopharm remains focused on advancing its clinical pipelines, particularly with its ongoing Phase 3 SENTRY Trial for myelofibrosis, which is nearing completion of patient enrollment. Richard Paulson, the President and CEO, expressed enthusiasm regarding their approach to potentially redefining treatment standards in myelofibrosis. Top-line data from the trial is expected to be reported in March 2026.

The ongoing demand for XPOVIO is notably robust, particularly in community settings that account for approximately 60% of the total product revenue. The company is also experiencing growth in royalty revenue stemming from partnerships with international firms such as Menarini and Antengene. In Q2 2025, royalty revenue increased by 28% year-over-year to $1.6 million.

Research Focus

Karyopharm is conducting several clinical trials targeting various cancers. In myelofibrosis, the SENTRY Trial, which targets 350 patients, evaluates the efficacy of selinexor in combination with ruxolitinib, relative to ruxolitinib plus placebo.

Additionally, the Phase 3 XPORT-EC-042 trial is evaluating selinexor as a maintenance treatment following systemic therapy in patients with advanced endometrial cancer. The company also completed enrollment for the Phase 3 XPORT-MM-031 trial, investigating a combination of selinexor, pomalidomide, and dexamethasone for multiple myeloma patients.

Financial Outlook and Strategy

The financial forecast for the full year 2025 comprises total revenues primarily from U.S. XPOVIO net product sales and associated licensing agreements. Karyopharm's projected expenditures for research and development, alongside selling, general, and administrative costs, are expected to be between $240 million to $250 million throughout the year.

Despite current challenges, including a significant net loss of $37.3 million in Q2, Karyopharm remains optimistic about its financial sustainability. The company is strategically working through potential financing avenues to maintain liquidity into 2026, especially as it approaches critical milestones in its clinical development pipeline.

In conclusion, Karyopharm Therapeutics is poised for substantial progress as it continues to innovate within the oncology sphere while managing its financial health strategically. The upcoming months will be crucial for both its clinical trials and financial trajectory, as the company navigates the complexities of the pharmaceutical industry.